Company Performance - MiMedx reported quarterly earnings of $0.1 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.08 per share a year ago [1] - The earnings surprise was +66.67%, with the company having surpassed consensus EPS estimates two times over the last four quarters [2] - Revenues for the quarter ended June 2025 were $98.61 million, surpassing the Zacks Consensus Estimate by 10.45%, and up from $87.21 million year-over-year [3] Stock Movement and Outlook - MiMedx shares have declined approximately 30.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [4] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [5] - The current consensus EPS estimate for the next quarter is $0.07 on revenues of $94.78 million, and $0.26 on revenues of $375.01 million for the current fiscal year [8] Industry Context - The Medical - Biomedical and Genetics industry, to which MiMedx belongs, is currently in the top 37% of over 250 Zacks industries, indicating a favorable industry outlook [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact MiMedx's stock performance [6]